Novartis Ireland Limited

Lobbying Organisation Novartis Ireland Limited

Date published 11 Sep, 2025

Relevant Matter Legislation

Public Policy Area Health

Period 1 May, 2025 to 31 Aug, 2025

Specific Details IPHA Industry meeting - engagement on trade and tariff issues

Intended results Ireland is seen as a country that values innovation and innovative new medicines

Name of person primarily responsible for lobbying on this activity Caitriona Walsh (as part of a group)

Did any Designated Public Official(DPO) or former Designated Public Official(DPO) carry out lobbying activities on your behalf in relation to this return? You must include yourself, and answer Yes, if you are a current DPO or a DPO at any time in the past. (What is a Designated Public Official?) Yes

Current or Former Designated Public Official(s)

Oliver OConnor (Former DPO) Adviser to Minister (Department of Health)

Did you manage or direct a grassroots campaign? No

Was this lobbying done on behalf of a client? No

Lobbying activity

The following activities occurred for this specific Subject Matter Area.

Meeting (1)

Discussion regarding the potential impact in Ireland of US tariffs on medicines. Also asking that Ireland shows that it values innovation and returns to its previous position of being an early launch country for new medicines, and that Ireland publicly supports maintaining RDP (regulatory data protection) at 8 years, in line with other EU countries.

Designated public officials lobbied

The following DPOs were lobbied during this return period on this specific Subject Matter Area. These DPOs were involved in at least one of the Lobbying Activities listed above, but not necessarily all of them. As returns are specific to a Subject Matter Area the above Lobbying Activities may be associated with multiple returns.

Simon Harris Minister (Department of Foreign Affairs)